**This event has run**

Day two of our main agenda is packed with exclusive case studies and interactive panel discussions exploring what the next generation of cell-based immunotherapies will entail. View all session titles and their bullet points in the full event guide for more detail.

7:50 am Registration & Breakfast

8:50 am Chair’s Opening Remarks

Advancing the Next-Generation of Cell-Based Immunotherapies

9:00 am Pharma Leaders Fireside Chat


  • Highlighting the synergies between cell-based therapies and vaccines to create a common framework for development
  • Sharing thoughts on how the intrinsic service component in the commercialisation of neoantigen therapies requires similar patient preparation, additional treatment, follow up, and a specialised workforce and how these fit into the ‘big pharma’ model
  • Identifying opportunities for shared collaboration across different pipelines and creating an outline to develop pipelines with a common thread across the industry to facilitate collaborations, mergers, and acquisitions

9:30 am Developing Multi-Specific Autologous T Cell Therapy Targeting Tumour Neoantigens


  • Understanding pokeAcell’s ImmPACT technology – Simple expansion of neoantigen-specific T cells directly from blood
  • Exploring how AI-predicted neoantigens are utilised to generate a multi-specific polyclonal functional T cell product

10:00 am An integrated AI approach for the prediction of Clinically Relevant Neoantigens


• Describing unique neoantigen discovery algorithms optimized for predicting neoantigen
presentation to the tumor cell surface, in an improved manner
• A machine learning ensemble approach is taken to variant calling, identifying accurately
tumor specific variants
• The AI platform is composed of numerous models integrated in deep learning layers to
predict bone fide neoantigens
• We illustrate validation in an infectious disease setting, and applications to significantly
improve the identification of neoantigen targets for personalized cancer immunotherapy

10:30 am Morning Refreshments & Structured Networking

Pioneering Dark Antigens for a Brighter Future

11:00 am Shining a Light on Dark Antigens & T Cell Biology to Treat a Broad Patient Population


  • Exploring the hidden depths of cancer and T cell biology to discover and characterise unconventional immunotherapy targets
  • Looking beyond the known proteome into the genomic dark matter to identify and characterise Dark Antigens uniquely presented on the surface of cancer cells by MHC receptors
  • Discussing the role of cloud-based technology to speed up the discovery and assessment process of candidate antigens

11:30 am Targeting a Novel Shared Tumour-Specific Antigen with T Cell Receptor Transduced T Cells for the Treatment of Cancer


  • Utilising transgenic T cell receptor (TCR)-based T cell therapies which are powerful to target TSAs
  • Representing tumour organoids as reliable and more physiologically relevant models to characterise TSA-specific TCRs in comparison to 2D established tumour cell lines

12:00 pm ERAP1 Inhibition to Generate Neoantigens & Drive Anti-Tumour Cell Killing

  • Peter Joyce Chief Executive Officer & Co-founder, Grey Wolf Therapeutics Ltd.


  • Targeting the endoplasmic reticulum in the antigen presentation pathway to create novel neoantigens in cancer
  • Increasing tumour visibility and extending the therapeutic benefit of immunotherapy to many more cancer patients
  • Presenting Grey Wolf’s 1st in class ERAP1 inhibitor as a therapeutic pipeline for opportunities

12:30 pm Lunch & Networking

Utilising Neoantigens for Antibody Targeting of Tumours

1:30 pm Antibody-Targeting of Tumour-Associated Carbohydrate Antigens (TACAs) for Passive Immunotherapies


  • Presenting TACAs as a novel class of targets exclusively expressed on tumour cells
  • Uncovering how TACAs drive tumour progression by mediating metastasis, induction of angiogenesis or down-modulation of the immune system and therefore are ideal targets to interfere with tumour progression and targeting for antibody-mediated cell killing
  • Outlining Tacalyx’s technology which allows the generation and characterisation of specific antibodies suitable for clinical development

2:00 pm Targeting Tumour Neoepitopes with Monoclonal Antibodies

  • Philip Arlen President & Chief Executive Officer, Precision BioLogic


  • Employing a unique cancer vaccine platform to develop monoclonal antibodies against functional tumour neo-antigens
  • Utilising innovative technologies and expertise in immunology, in addition to unique antibody display platforms with an automated high throughput screening
  • Using these antibodies to identify the precise neoantigen targeted

2:30 pm Afternoon Refreshments & Structured Networking

Evaluating Combination Therapies to Maximise Anti-Tumour Immune Activity

3:00 pm Dendritic Cells & Their Role in Immunotherapy


• Presenting a new class of cancer vaccine based on an off-the-shelf Antigen Presenting Cell line (PDC*line)
• Discussing a new potent and scalable therapeutic cancer vaccine based on a proprietary allogeneic cell line of Plasmacytoid Dendritic Cells
• Understanding how the PDC*line is much more potent to prime and boost antitumour antigen, including neoantigens, specific cytotoxic T cells than conventional vaccines and improves the response to checkpoint inhibitors

3:30 pm Clinical Combination Strategies with Oncolytic Vaccines in Solid Tumours


• Harnessing the clinical activity of oncolytic adenoviral vector ONCOS-102 in solid tumours of different origin
• Identifying strong and consistent patterns of immuno-modulation with both PD1 blockade and chemotherapy
• Utilising the selection of future combination strategies based on tumour biopsy translational data

4:00 pm Panel Discussion – Evaluating Combination Therapies to Maximise Anti-Tumour Immune Activity


• What is the ideal combination strategy for neoantigen vaccines?
• What are the best combination therapies that maximise T cell responses and efficacy?
• How to identify a clear biologic effect caused by combination
• Improving clinical efficacy through immunotherapy combinations

4:30 pm Chair’s Closing Remarks